Several other TMPRSS2:ERG fusion events with different junction sites have also been described to occur in prostate cancer clinical samples with lower frequency (Kumar-Sinha et al., 2008; Weier et al., 2013). This evidence concerns the gene TMPRSS2 and prostate carcinoma.